A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)

Trial Profile

A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 29 Jan 2018 Results (n=380) of pooled data from six trials assessing population pk and exposure-response relationships for the antibody-drug conjugate brentuximab vedotin in ctcl patients, were published in the Clinical Pharmacology and Therapeutics.
    • 03 Oct 2017 Results assessing 5-year efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma, published in the Blood
    • 03 Oct 2017 Results presented in a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top